Prof. Andrew JS Coats on the STRONG-HF study

Heart failure (HF) is a major cause of disability globally, with a prevalence of approximately 1-2% of the adult population in developed countries [1].
In June, 2023, Roche Diagnostics Australia was delighted to speak with Professor Andrew JS Coats, Scientific Director and CEO, Heart Research Institute, Sydney.
Prof. Coats was kind enough to share his thoughts on heart disease in an Australian context. He offered his insights into the STRONG-HF study, including the nature of the trial and its implications for Australia and the world.
Prof. Coats noted that heart failure prevalence is increasing due to an aging population, as well as prolonged survival of HF patients due to the availability of effective diagnostic and therapeutic interventions, [1]. However, HF prognosis remains poor, with a 5-year survival rate of approximately 50% [2]. The STRONG-HF study demonstrates that rapid up-titration of GDMT and rigorous monitoring mediated by NT-proBNP improves patient outcomes [3].
Reference 1 - A. J. S. Coats, "Ageing, demographics, and heart failure," European Heart Journal Supplements, vol. 21, no. Supplement_L, pp. L4-L7, 2019, doi: 10.1093/eurheartj/suz235.
Reference 2 - Lopez - Sendon J. The Heart Failure Epidemic. Medicographia 2011; 33: 363-369
Reference 3 - A. Mebazaa et al., "Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial," The Lancet, vol. 400, no. 10367, pp. 1938-1952, 2022/12/03/ 2022, doi: doi.org/10.101....
Follow us on LinkedIn: / roche-digital-innolab
Subscribe to our KZbin channel now: www.youtube.co....
Get in touch with us:
www.roche.com/
/ roche
/ roche
/ roche
/ roche
Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.
Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.
For more information and insights visit: www.roche.com/